Trump Administration Unveils Up to 100% Tariff on Branded Drugs

Drugmakers or countries that strike pricing deals or make manufacturing investment commitments in the U.S. can secure much lower levies, or none at all.

Apr. 2, 2026 at 7:41pm

Got story updates? Submit your updates here. ›

A photorealistic oil painting of a single prescription medication bottle or pill capsule sitting on a wooden surface, with warm sunlight casting dramatic shadows across the scene, conceptually representing the administration's trade policy approach to drug pricing.The Trump administration's new tariffs on imported branded drugs aim to pressure pharmaceutical companies to lower prices for American consumers.NYC Today

The U.S. government announced it will impose tariffs of up to 100% on branded pharmaceutical imports, though nations or drugmakers that strike deals with the Trump administration or commit to build manufacturing facilities in the U.S. can receive lower levies.

Why it matters

This move is part of the Trump administration's ongoing efforts to lower prescription drug prices in the U.S. by leveraging trade policy to pressure pharmaceutical companies and foreign governments to offer better pricing for American consumers.

The details

The 100% tariff will apply to patented imported pharmaceuticals from companies that haven't committed to invest in the U.S. and haven't entered into 'most favored nation' agreements to match their U.S. prices to the lowest they charge in other developed countries.

  • The White House announced the new tariffs on Thursday, April 2, 2026.

The players

Trump Administration

The executive branch of the U.S. federal government under former President Donald Trump, which is seeking to lower prescription drug prices through trade policy.

Got photos? Submit your photos here. ›

What’s next

The new tariffs are expected to go into effect in the coming months, with details on implementation and enforcement still to be determined by the administration.

The takeaway

This aggressive trade action represents the Trump administration's latest attempt to address high drug prices, though its long-term impact on the pharmaceutical industry and consumer costs remains to be seen.